In acute myeloid leukemia (AML), activating mutations in the fms-like tyrosine kinase 3 (FLT3) gene predict poor prognosis. We determined FLT3 internal tandem duplications (FLT3/ITD) and D835 point mutations in paired initial and relapse samples from 80 pediatric and adult AML patients. One D835 point mutation was found in an initial pediatric AML sample. Fms-like tyrosine kinase 3/ITDs were present in 21 initial and 22 relapse samples (26.3 and 27.5%, respectively). Interestingly, FLT3/ITD positivity was related to a significantly shorter time to relapse, most pronounced when the ITD-positive status was found at relapse (Po0.001). However, FLT3/ITD status changed between diagnosis and relapse in 14 cases. In four patients, the FLT3/ITD became undetectable at relapse in five patients FLT3/ITDs were only detected at relapse, and in five patients the length or number of FLT3/ITDs changed. Gain of FLT3/ITDs may suggest oligoclonality with selective outgrowth of the FLT3/ITD-positive clone, whereas losses may reflect ITDs in the more mature leukemic cells rather than in the leukemic stem cell, or, alternatively, that other genetic aberrations provided a greater selective advantage. Studying FLT3/ITD kinetics in minimal residual disease setting may provide some answers for the changes we observed. Fms-like tyrosine kinase 3/ITD is a relevant marker for prognosis, and remains an important target for therapeutic inhibition.
Introduction
The fms-like tyrosine kinase 3 (FLT3) gene encodes a class III receptor tyrosine kinase that is predominantly expressed on hematopoietic progenitor cells, but is also found on a spectrum of hematologic malignancies. 1 Fms-like tyrosine kinase 3 plays an important role in stem cell proliferation, differentiation and survival, and activating mutations, cooperating with fusion genes, have been related to leukemogenesis. 2 At least two types of FLT3 mutations have been found in leukemic cells that induce ligand-independent FLT3 dimerization and constitutive activation through autophosphorylation leading to increased and uncontrolled cell proliferation: (1) internal tandem duplication (ITD) mutations of the juxtamembrane domain 3 (2) point mutations such as in aspartic acid 835 (D835) within the activation loop of the second tyrosine kinase domain. 4 The frequency of FLT3/ITD in adult patients with acute myeloid leukemia (AML) is approximately 20-30%, whereas a lower incidence of FLT3/ITD in children has been reported (5-22%). For both age groups, the presence of an ITD has been related to poor prognosis. 5, 6 The impact of D835 point mutations on prognosis is less clear, possibly because it is more difficult to show a significant influence with the low patient numbers as D835 point mutations occur less frequent (7%). It may also be that the D835 point mutations are not related to prognosis because of their different influence on cell signaling as compared to the FLT3/ITD. Fms-like tyrosine kinase 3/ITD has been suggested to serve as additional parameter in the determination of minimal residual disease (MRD), with the aim to predict relapse. However, this approach is controversial owing to indications that FLT3 status may change owing to treatment. To gain further insight into the role of FLT3/ITD and FLT3 D835 mutations in the development of relapses, we analyzed paired initial and relapse samples from a large cohort (n ¼ 80) of patients with AML.
Materials and methods
Bone marrow or peripheral blood samples were collected, after informed consent was obtained, from both pediatric (n ¼ 42) and adult (n ¼ 38) AML patients at initial diagnosis and at relapse. All included pairs had similar French-American-British types at diagnosis and relapse, whereas cytogenetic data were predominantly only determined for the initial sample. Pediatric samples were obtained from the VU University Medical Center (VUmc), the Dutch Childhood Oncology Group and the AML Berlin-Frankfurt-Munster Group, whereas adult samples were obtained from the VUmc and the University of Leuven. Cytogenetic data were classified in three risk groups according to the Medical Research Council AML criteria (without taking response to treatment into consideration). Time to relapse was determined as the number of months between initial diagnosis and relapse.
Genomic DNA was obtained from cytospin slides or frozen cell pellets, and of eight samples RNA was isolated. Fms-like tyrosine kinase 3/ITD was analyzed by polymerase chain reaction amplification according to the method of Kiyoi et al., 8 but with an FAM-labeled 12R reverse primer. Product lengths were measured on an ABI PRISM sequencer (310 Genetic Analyzer; Applied Biosystems, Foster City, CA, USA) and analyzed using GeneScan Analysis software (version 1.2, Applied Biosystems). Fms-like tyrosine kinase 3/D835 mutations were determined in DNA samples when material was available (n ¼ 53), by LightCycler analysis (Roche diagnostics GmbH, Mannheim, Germany) using primers (forward: FLT3_S 5 0 -gg tgaagatatgtgactttggat; reverse: FLT3_R 5 0 -attatagatggaagatt ccctgaa) and a specific labeled probe covering the mutation (anchor: FLT3_anchor 5 0 -aaatagcagcctcacattgcccctg-FL; sensor: FLT3_sensor wild-type (wt) 5 0 LC Red705-gttggaatcactcatgatatcc gag-PH). After amplification, melting curves were analyzed for the presence of point mutations.
Statistical analysis
Data were analyzed with Mann-Whitney U-test, Spearman's rank correlation and analysis of variance. After log transformation, combined influences on time to relapse were explored using multiple regression analysis. SPSS Statistical software version 11.0 for Windows (SPSS Inc., Chicago, IL, USA) was used. All analyses were two-tailed and differences were considered statistically significant when P-values were o0.05.
Results and discussion
We successfully screened a total of 160 samples, comprising 80 paired initial and relapse samples for length mutations, and 53 pairs for the FLT3 D835 point mutation. The point mutation group was smaller owing to the lack of cells either from the diagnostic or relapse sample in 27 pairs. Table 1 summarizes the patient characteristics.
In a control experiment, it was shown that 0.8% FLT3/ITDpositive cells (MV4-11) and o5% FLT3 D835 point mutationpositive cells could still be detected in a background of wt cells (HL60), indicating that only smaller subclones may have been missed. Our samples contained at least 5% blasts, which is defined in the classical morphological criteria for AML.
At initial diagnosis, 21 patients (26.3%) had a FLT3/ITD, which is similar to the frequency at relapse (n ¼ 22, 27.5%), as also shown in previous studies by others. 9, 10 However, FLT3/ ITD status changed in 14 patients between diagnosis and relapse, and included both occurrences and disappearances of FLT3/ITDs, as well as changes in the length or number of mutations (Table 2) . Representative examples are shown in Figure 1 . Fms-like tyrosine kinase 3/ITD positivity was related to a significantly (Po0.03) shorter time to relapse (7.8 vs 12.6 months), but more pronounced (Po0.001) when the ITDpositive status was found at relapse (6.6 vs 13.5 months). Interestingly, the relatively short time to relapse was also found in the five patients who were initially FLT3/ITD negative but gained an FLT3/ITD at relapse, and for the five patients who had a different length or number of FLT3/ITDs at relapse (Table 2) . Moreover, the four patients who lost their FLT3/ITD at relapse had a longer time to relapse, comparable to FLT3/ITD-negative patients. Although the time to relapse was slightly longer in children when compared with adults, the relation between FLT3/ITD positivity and time to relapse was significant both in children (6.3 months in FLT3/ITD positive vs 16.2 months in FLT3/ITD negative; Po0.0001) and adults (7.3 months in FLT3/ ITD positive vs 10.9 months in FLT3/ITD negative; Po0.002), respectively. Age, blast percentage and white blood cell count were not significantly correlated to time to relapse in this selected cohort. Although the relatively small number of patients with poor risk cytogenetics relapsed earlier, this was not statistically significant (P ¼ 0.17), when compared to patients from the other two cytogenetic risk groups. In multiple regression analysis, correcting for FLT3/ITD positivity at relapse /l) at diagnosis and the blast percentage represents the fraction of leukemic cells in a background of normal WBCs isolated from blood or bone marrow at diagnosis. p25-75 are the 25 and 75 percentiles. Of 53 paired samples tested, one D835 mutation was found in an intial sample, which was lost at relapse. Cytogenetic risk groups were stratified according to the MRC strategy and data were available of 53 cases.
was the only significant parameter predicting time to relapse (P ¼ 0.012). The follow-up data after relapse were limited and did not allow for statistical analysis of overall survival time.
At this stage, it cannot be excluded that what we report as gains of FLT3/ITDs can be explained by oligoclonality in the initial diagnosis samples, with subclones that were below the detection limit of our assay. Of interest in this respect is that recent data suggest that FLT3/ITDs can be present in leukemic stem cells. 11 Our results suggest that, when the bulk of AML cells has been eradicated by therapy, remaining FLT3/ITDpositive leukemic stem cells may result in an early relapse. Alternatively, the gain of an FLT3/ITD may be explained by development of a de novo mutation, which is less likely in the relatively short period of time (76 months). However, genotoxic stress by intensive chemotherapy may result in an increased mutation induction, and genotoxic exposure has been linked to the occurrence of FLT3/ITDs. 12 To explain the losses of FLT3/ITDs at relapse, we hypothesize that in these cases an FLT3/ITD positive was acquired in the more mature leukemic cells, which were successfully eradicated, but not in the leukemic stem cell. This may also explain why most, but not all patients with an FLT3/ITD have a poor prognosis. 6 Whether the loss of an FLT3/ITD may coincide with other genetic abnormalities that confer a greater selective survival advantage to the leukemic cells at relapse has yet to be elucidated but is in agreement with our earlier observation that the growth-promoting mutations are usually mutually exclusive. 13 A recently published exception is the NPM1 mutation, which is frequently found in adult AML (725%) and often coincides with FLT3/ITD. Although they showed that the NPM1 mutation is stable during disease evolution, the relation with the pathogenesis of AML is not established yet. 14 The exact blast percentages at relapse were only available for a minority of patients. However, as relapse was defined by classical morphological criteria (i.e. more than 5% blasts in the bone marrow), it is unlikely that the lower blast percentage explains the loss of FLT3/ITD, given the sensitivity of our test.
In the five samples where the length of the ITD mutation had changed at relapse, we found samples with more than one length mutation at diagnosis where either one was gained or lost and samples where only one length mutation was present at diagnosis and another one at relapse. In the latter cases, we do not know whether this comprises the loss of one particular clone and a gain of another clone, or that the length of the ITD changed during therapy. In general, the overall FLT3/ITD lengths ranged from 21 to 219 bp and there was no correlation in samples having changes in FLT3/ITD (range: 21-150 bp) with loss or gains of smaller or longer ITDs.
The high number of FLT3/ITD-positive samples that change during treatment and the relation between FLT3/ITD at relapse and short time to relapse is in agreement with data by Tiesmeier et al., 15 who reported that in a relatively small cohort of 31 paired AML samples, five out of nine FLT3/ITD-positive patients showed changes (one gain, three losses and one change). To gain more insight into the biology of these changes in FLT3/ITD status, it will be crucial to determine the FLT3/ITD kinetics in serial MRD samples, using a more sensitive FLT3/ITD detection method (possibly patient specific). 16 Moreover, further studies are needed to study oligoclonality in diagnostic samples, including flowcytometry-sorted leukemic stem cells (Wright JA et al. Blood 2005; 106: 227; abstract).
Only one D835 point mutation was found in a newly diagnosed pediatric sample, but not at relapse. The relation between D835 mutations and prognosis is not as clear as for the FLT3/ITD status. Of interest, the percentage of D835 point mutations in this cohort of relapsed patients is remarkably low. This suggests that FLT3 point mutations may not be involved in the development of relapse, as we would have expected a selection of patients with a higher frequency of these mutations in that case.
In conclusion, in these paired samples, FLT3/ITD positivity is related to a significantly shorter time to relapse, which once more stresses the need for effective FLT3 inhibitors for treatment.
